Pfizer Inc. (PFE) Shares Bought by Ironvine Capital Partners LLC

Ironvine Capital Partners LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 59.0% during the second quarter, HoldingsChannel.com reports. The fund owned 56,632 shares of the biopharmaceutical company’s stock after purchasing an additional 21,010 shares during the period. Ironvine Capital Partners LLC’s holdings in Pfizer were worth $2,055,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ballew Advisors Inc acquired a new position in Pfizer in the first quarter worth approximately $102,000. Earnest Partners LLC acquired a new position in Pfizer in the fourth quarter worth approximately $105,000. Woodard & Co. Asset Management Group Inc. ADV acquired a new position in Pfizer in the fourth quarter worth approximately $118,000. W.G. Shaheen & Associates DBA Whitney & Co acquired a new position in Pfizer in the first quarter worth approximately $132,000. Finally, Bray Capital Advisors acquired a new position in Pfizer in the first quarter worth approximately $139,000. Institutional investors and hedge funds own 68.91% of the company’s stock.

In related news, VP Loretta V. Cangialosi sold 26,814 shares of the firm’s stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $40.16, for a total value of $1,076,850.24. Following the completion of the transaction, the vice president now owns 102,360 shares of the company’s stock, valued at approximately $4,110,777.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Laurie J. Olson sold 10,214 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the transaction, the insider now directly owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The disclosure for this sale can be found here. Insiders sold a total of 761,230 shares of company stock valued at $29,054,690 in the last ninety days. Company insiders own 0.06% of the company’s stock.

Pfizer stock opened at $43.90 on Friday. Pfizer Inc. has a 52 week low of $33.20 and a 52 week high of $44.46. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91. The company has a market capitalization of $260.68 billion, a P/E ratio of 16.57, a PEG ratio of 2.21 and a beta of 0.96.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm had revenue of $13.47 billion during the quarter, compared to analyst estimates of $13.30 billion. During the same quarter last year, the business posted $0.67 EPS. The company’s revenue was up 4.4% on a year-over-year basis. equities analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.10%. Pfizer’s dividend payout ratio is 51.32%.

Several research analysts have issued reports on the stock. Cantor Fitzgerald set a $45.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday. Barclays restated a “neutral” rating and issued a $40.00 price target on shares of Pfizer in a research report on Wednesday. Morningstar set a $46.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Thursday. Morgan Stanley set a $45.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Thursday, September 13th. Finally, JPMorgan Chase & Co. set a $42.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, September 10th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company. Pfizer presently has an average rating of “Hold” and an average price target of $41.89.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

See Also: Average Daily Trade Volume – What You Need to Know

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply